DK2366409T3 - Termosensitiv sammensætning som forhindrer vævsadhæsion og fremgangsmåde til fremstilling deraf - Google Patents
Termosensitiv sammensætning som forhindrer vævsadhæsion og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK2366409T3 DK2366409T3 DK09827667.8T DK09827667T DK2366409T3 DK 2366409 T3 DK2366409 T3 DK 2366409T3 DK 09827667 T DK09827667 T DK 09827667T DK 2366409 T3 DK2366409 T3 DK 2366409T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- copolymer
- group
- thermosensitive
- tissue adhesion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 81
- 208000031737 Tissue Adhesions Diseases 0.000 title claims description 51
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 238000004132 cross linking Methods 0.000 claims description 19
- 238000005507 spraying Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 229920001400 block copolymer Polymers 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 12
- 238000002835 absorbance Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- -1 hydroxylamine compound Chemical class 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 229920001451 polypropylene glycol Polymers 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 108010039627 Aprotinin Proteins 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229960004405 aprotinin Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- 229960001017 tolmetin Drugs 0.000 claims description 3
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 229960003121 arginine Drugs 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 229960002433 cysteine Drugs 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229940049906 glutamate Drugs 0.000 claims 2
- 229960002743 glutamine Drugs 0.000 claims 2
- 229960002449 glycine Drugs 0.000 claims 2
- 229960002885 histidine Drugs 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 229960003646 lysine Drugs 0.000 claims 2
- 235000006109 methionine Nutrition 0.000 claims 2
- 229960004452 methionine Drugs 0.000 claims 2
- 229960005190 phenylalanine Drugs 0.000 claims 2
- 229960002429 proline Drugs 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960002898 threonine Drugs 0.000 claims 2
- 229960004799 tryptophan Drugs 0.000 claims 2
- 229960004441 tyrosine Drugs 0.000 claims 2
- 229960004295 valine Drugs 0.000 claims 2
- 235000014393 valine Nutrition 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 238000001429 visible spectrum Methods 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 15
- 239000003431 cross linking reagent Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 11
- 230000007704 transition Effects 0.000 description 8
- 229920005615 natural polymer Polymers 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940116024 aftera Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000013129 endoscopic sinus surgery Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- XFLNVMPCPRLYBE-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O XFLNVMPCPRLYBE-UHFFFAOYSA-J 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polymers & Plastics (AREA)
Claims (11)
1. Termosensitiv sammensætning egnet til at forhindre vævsadhæsion, fremstillet via en kemisk reaktion ved at spraye og røre c) 0,01 til 2 vægtprocent af et cross-linking stof i en vandig opløsning omfattende: a) 1 til 50 vægtprocent af en blok-copolymer som har en molekylevægt på 1.000 til 500.000 g/mol og omfatter en polyethylenoxidblok; og b) 0,5 til 1 vægtprocent afen polymersom haren molekylevægt på 10.000 til 1.000.000 g/mol og er i stand til at blive blandet med a) blok-copolymeren; hvor cross-linking stoffet er en eller flere valgt fra gruppen bestående af forbindelser som inkluderer en eller flere kationer valgt fra gruppen bestående af Mg2+, Mn2+, Ca2+, Co2+, Cu2+, Sr2+, Ba2+, Fe2+; kitosan; glutaraldehyd; formalin; poly-L-lysin; akrylsyrepolymerer af polyakrylsyre og polymethakrylsyre; en hydroxylamin forbindelse af dopamin; isoleucin, phenylalanin, leucin, threonin, lysin, tryptofan, metionin, valin, histidin, alanin, arginin, asparagin, aspartat, cystein, glutamin, glutamat, glycin, prolin, serin og tyrosin; og i hvilken en forskel i viskositet mellem et øvre og nedre væskelag er inden for 10 % når sammensætningen centrifugeres i 3 minutter ved 3.000 rpm og 25 °C.
2. Termosensitiv sammensætning ifølge krav 1, hvor en forskel i absorbans mellem det øvre og nedre væskelag er inden for 10 % ved bølgelængder fra 400 til 750 nm i det synlige spektrum.
3. Termosensitiv sammensætning ifølge krav 1 eller krav 2, hvor en forskel i stabilitet mellem det øvre og nedre væskelag er inden for 10 %.
4. Termosensitiv sammensætning ifølge et hvilket som helst af kravene 1 til 3, hvor sammensætningen er fremstillet ved at spraye og røre cross-linking stoffet med en spraypartikeldiameter på 5 til 500 pm til den vandige opløsning omfattende a) copolymeren og b) polymeren.
5. Termosensitiv sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvor sammensætningen endvidere omfatter et eller flere lægemidler valgt fra gruppen bestående aftrombin, aprotinin, steroid anti-inflammatoriske midler og non-steroide anti-inflammatoriske midler (NSAIDs), heparin, vævsplasminogenaktivator, ibuprofen, naproxen, tolmetin, og indomethacin.
6. Termosensitiv sammensætning ifølge krav 5, hvor indholdet af lægemidlet er 0,01 til 50 vægtprocent baseret på sammensætningen.
7. Termosensitiv sammensætning ifølge et hvilket som helst af kravene 1 til 6, hvor a) copolymeren er en eller flere valgt fra gruppen bestående af polyethylene-polypropylenoxid-copolymer (Pluronic serie), polyethylenoxid-polymælkesyre copolymer, polyethylenoxid-polymælkeglykolsyre copolymer, og polyethylenoxid-polycaprolacton copolymer; og/eller hvor b) polymeren er en eller flere valgt fra gruppen bestående af chondroitinsulfat, dermatansulfat, keratansulfat, heparansulfat, alginsyre, hyaluronsyre, carboxymethylcellulose, dextran, collagen, gelatine, elastin, og fibrin.
8. Fremgangsmåde til fremstilling afen termosensitiv sammensætning egnet til at forhindre vævsadhæsion, omfattende: fremstilling afen vandig opløsning omfattende; a) 1 til 50 vægtprocent af en blok-copolymer som har en molekylevægt på 1.000 til 500.000 g/mol og omfattende en polyethylenoxidblok; og b) 0,5 til 1 vægtprocent afen polymer med molekylevægt på 10.000 til 1.000.000 g/mol der er i stand til at blive blandet med a) blok-copolymeren; og at spraye og røre c) 0,01 til 2 vægtprocent af et cross-linking stof med en spraypartikeldiameter på 5 til 500 pm til den vandige opløsning, hvor cross-linking stoffet er en eller flere valgt fra gruppen bestående af forbindelser som inkluderer en eller flere kationer valgt fra gruppen bestående af Mg2+, Mn2+, Ca2+, Co2+, Cu2+, Sr2+, Ba2+, Fe2+; kitosan; glutaraldehyd; formalin; poly-L-lysin; akrylsyrepolymerer af polyakrylsyre og polymethakrylsyre; en hydroxylamin forbindelse af dopamin; isoleucin, phenylalanin, leucin, treonin, lysin, tryptofan, metionin, valin, histidin, alanin, arginin, asparagin, aspartat, cystein, glutamin, glutamat, glycin, prolin, serin og tyrosin; og hvor en sprayhastighed er 10 til 100 ml/min, og en rørehastighed er 300 rpm til 1500 rpm.
9. Fremgangsmåde til fremstilling afen termosensitiv sammensætning ifølge krav 8, hvor den vandige opløsning er fremstillet ved at opløse a) copolymeren og b) polymeren i en saltopløsning, fortrinsvis hvor saltopløsningen er en eller flere valgt fra gruppen bestående afen isotonisk saltopløsning, fosfatbufferopløsning, organisk saltbufferopløsning og bikarbonatbufferopløsning.
10. Fremgangsmåde til fremstilling afen termosensitiv sammensætning ifølge krav 8 eller krav 9, hvor sammensætningen endvidere omfatter et eller flere lægemidler valgt fra gruppen bestående af trombin, aprotinin, steroid anti-inflammatoriske midler og non-steroide anti-inflammatoriske midler (NSAIDs), heparin, vævsplasminogenaktivator, ibuprofen, naproxen, tolmetin, og indomethacin, fortrinsvis hvor indholdet af lægemidlet er 0,01 til 50 vægtprocent baseret på sammensætningen.
11. Termosensitiv sammensætning ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i forhindring af vævsadhæsion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080114946A KR101125934B1 (ko) | 2008-11-19 | 2008-11-19 | 열감응성 조직 유착 방지 조성물 및 이의 제조 방법 |
| PCT/KR2009/005280 WO2010058902A2 (ko) | 2008-11-19 | 2009-09-17 | 열감응성 조직 유착 방지 조성물 및 이의 제조 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2366409T3 true DK2366409T3 (da) | 2015-01-12 |
Family
ID=42198618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09827667.8T DK2366409T3 (da) | 2008-11-19 | 2009-09-17 | Termosensitiv sammensætning som forhindrer vævsadhæsion og fremgangsmåde til fremstilling deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9095643B2 (da) |
| EP (1) | EP2366409B1 (da) |
| JP (1) | JP5604440B2 (da) |
| KR (1) | KR101125934B1 (da) |
| CN (1) | CN102245212B (da) |
| DK (1) | DK2366409T3 (da) |
| ES (1) | ES2526453T3 (da) |
| PL (1) | PL2366409T3 (da) |
| PT (1) | PT2366409E (da) |
| WO (1) | WO2010058902A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013015579A2 (ko) * | 2011-07-26 | 2013-01-31 | (주)차바이오앤디오스텍 | 콜라겐 및 히알루론산 유도체를 포함하는 의료용 복합 생체 소재 |
| KR101330652B1 (ko) * | 2012-02-28 | 2013-11-18 | (주)시지바이오 | 성장인자 담지 가능한 유착방지용 고분자 조성물 |
| KR101389831B1 (ko) * | 2012-05-25 | 2014-05-07 | 한남대학교 산학협력단 | 온도 감응형 유착방지제 |
| US20150209481A1 (en) * | 2012-08-16 | 2015-07-30 | Nipro Corporation | Antiadhesive Material |
| CN104027850A (zh) * | 2014-06-03 | 2014-09-10 | 陈凯 | 一种术后冲洗剂及其制备方法 |
| KR101627787B1 (ko) | 2014-07-24 | 2016-06-07 | 주식회사 메디톡스 | 열감응성 유착 방지용 조성물 및 그의 용도 |
| PL409231A1 (pl) * | 2014-08-21 | 2016-02-29 | Warszawski Uniwersytet Medyczny | Sposób wytwarzania gwoździ śródszpikowych z chitozanu do leczenia złamań kości długich |
| KR101852718B1 (ko) * | 2017-04-04 | 2018-05-18 | 주식회사 제네웰 | 외과수술 후 절개부위 통증 감소를 위한 키트 |
| KR101923734B1 (ko) | 2017-04-13 | 2018-11-29 | 영남대학교 산학협력단 | 유착 방지용 가교 필름 |
| KR101981562B1 (ko) * | 2017-05-04 | 2019-05-24 | 주식회사 테라시온 바이오메디칼 | 유착방지용 조성물의 제조방법 |
| CN108159508B (zh) * | 2018-01-03 | 2021-01-26 | 东南大学 | 一种防粘连医用水凝胶材料的制备方法 |
| KR101902956B1 (ko) | 2018-03-13 | 2018-10-02 | 주식회사 제네웰 | 외과수술 후 절개부위 통증 감소를 위한 키트 |
| KR102065016B1 (ko) | 2018-04-17 | 2020-01-10 | 주식회사 제네웰 | 외과수술 후 절개부위 통증 감소 또는 치료를 위한 키트 |
| KR102144479B1 (ko) * | 2018-05-24 | 2020-08-13 | 주식회사 덱스레보 | 조직 수복용 조성물 및 이의 제조방법 |
| KR102251192B1 (ko) * | 2020-08-07 | 2021-05-13 | 주식회사 덱스레보 | 조직 수복용 조성물 및 이의 제조방법 |
| CN117618533B (zh) * | 2023-11-28 | 2024-08-06 | 上海市第四人民医院 | 一种光敏固化喷剂及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4271281A (en) * | 1980-05-29 | 1981-06-02 | American Hoechst Corporation | Process for preparing styrenic polymer particles |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4983585A (en) * | 1987-05-04 | 1991-01-08 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
| JP3536186B2 (ja) * | 1995-02-27 | 2004-06-07 | 独立行政法人 科学技術振興機構 | 生体内分解性高分子ヒドロゲル |
| US5939485A (en) | 1995-06-19 | 1999-08-17 | Medlogic Global Corporation | Responsive polymer networks and methods of their use |
| US6696499B1 (en) * | 1996-07-11 | 2004-02-24 | Life Medical Sciences, Inc. | Methods and compositions for reducing or eliminating post-surgical adhesion formation |
| JPH10235230A (ja) | 1997-02-28 | 1998-09-08 | Igarashi Kogyo Kk | 油処理剤散布装置 |
| JP2000281794A (ja) | 1999-03-30 | 2000-10-10 | Dainippon Ink & Chem Inc | 吸水性樹脂の製造方法 |
| EP1181023B1 (en) | 1999-04-02 | 2008-08-13 | Fziomed, Inc. | Compositions of polyacids, non-ionic polymers consisting of alkylene oxide monomers and multivalent cations and their use in reducing adhesions |
| KR20030050953A (ko) | 2001-12-20 | 2003-06-25 | 주식회사 하이닉스반도체 | 반도체 소자의 다층금속배선 형성방법 |
| DE10220494A1 (de) * | 2002-05-07 | 2003-11-20 | Basf Ag | Verfahren zur Herstellung einer wässrigen Alkaliacrylat-Lösung |
| KR100565881B1 (ko) * | 2003-07-24 | 2006-03-29 | 이진호 | 생체적합성 공중합체를 이용한 조직유착 방지제 |
| JP2005139293A (ja) | 2003-11-06 | 2005-06-02 | Mitsui Chemicals Inc | ゴム架橋用硫黄分散液 |
| JP5026665B2 (ja) | 2004-10-15 | 2012-09-12 | 株式会社フジミインコーポレーテッド | 研磨用組成物及びそれを用いた研磨方法 |
-
2008
- 2008-11-19 KR KR1020080114946A patent/KR101125934B1/ko active Active
-
2009
- 2009-09-17 CN CN200980149694.2A patent/CN102245212B/zh active Active
- 2009-09-17 ES ES09827667.8T patent/ES2526453T3/es active Active
- 2009-09-17 PL PL09827667T patent/PL2366409T3/pl unknown
- 2009-09-17 WO PCT/KR2009/005280 patent/WO2010058902A2/ko not_active Ceased
- 2009-09-17 DK DK09827667.8T patent/DK2366409T3/da active
- 2009-09-17 PT PT98276678T patent/PT2366409E/pt unknown
- 2009-09-17 EP EP09827667.8A patent/EP2366409B1/en active Active
- 2009-09-17 JP JP2011537345A patent/JP5604440B2/ja active Active
- 2009-09-17 US US13/129,765 patent/US9095643B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2366409T3 (pl) | 2015-03-31 |
| EP2366409A2 (en) | 2011-09-21 |
| CN102245212B (zh) | 2014-06-18 |
| JP2012509129A (ja) | 2012-04-19 |
| JP5604440B2 (ja) | 2014-10-08 |
| EP2366409B1 (en) | 2014-12-10 |
| WO2010058902A3 (ko) | 2010-07-15 |
| KR20100056009A (ko) | 2010-05-27 |
| KR101125934B1 (ko) | 2012-03-21 |
| CN102245212A (zh) | 2011-11-16 |
| PT2366409E (pt) | 2015-01-13 |
| US9095643B2 (en) | 2015-08-04 |
| US20110229432A1 (en) | 2011-09-22 |
| ES2526453T3 (es) | 2015-01-12 |
| WO2010058902A2 (ko) | 2010-05-27 |
| EP2366409A4 (en) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2366409T3 (da) | Termosensitiv sammensætning som forhindrer vævsadhæsion og fremgangsmåde til fremstilling deraf | |
| Xia et al. | Adhesive hemostatic hydrogel with ultrafast gelation arrests acute upper gastrointestinal hemorrhage in pigs | |
| US10159742B2 (en) | Hydrogel compositions | |
| KR101766679B1 (ko) | 유착 방지를 위한 히드로겔 막 | |
| CN104888263B (zh) | 生物相容性止血、防粘连、促愈合、外科封闭的变性淀粉材料 | |
| EP2100628B1 (en) | Self-degradable adhesive for medical use of two- component reactant system comprising powder-powder | |
| EP2332553A1 (en) | Methods and compositions to treat myocardial conditions | |
| JP5963130B2 (ja) | 生体組織補強材料キット及び生体組織補強材料 | |
| JP2014530889A (ja) | 止血組成物 | |
| TW200924804A (en) | A bone and/or dental cement composition and uses thereof | |
| US20130098550A1 (en) | Functionalized adhesive for medical devices | |
| Atashgahi et al. | Epinephrine-entrapped chitosan nanoparticles covered by gelatin nanofibers: A bi-layer nano-biomaterial for rapid hemostasis | |
| Salmasi et al. | Polysaccharide-based (kappa carrageenan/carboxymethyl chitosan) nanofibrous membrane loaded with antifibrinolytic drug for rapid hemostasis-in vitro and in vivo evaluation | |
| WO2020137903A1 (ja) | 粉体、創傷被覆材、癒着防止材、止血材、及び紛体の製造方法 | |
| KR20230057168A (ko) | 케라틴 결합 피브리노겐 하이드로겔을 유효성분으로 포함하는 지혈제 조성물 | |
| JP2021184795A (ja) | 組織癒着防止用温度感受性組成物およびその用途 | |
| JP3560916B2 (ja) | ふっ素化ポリマー類を用いた外科手術における術後の癒着および組織損傷を防止するための方法および組成物 | |
| FR2754183A1 (fr) | Composition visqueuse hemostatique, notamment a l'etat de gel | |
| JP2006111867A (ja) | 光反応性多糖、その光架橋多糖生成物及び医用材料 | |
| CN114522277A (zh) | 一种原位凝胶的设计合成及其在去除结石与碎片药物中的应用 | |
| EP4630006A1 (en) | Flowable chitosan bioadhesive hemostatic compositions that resist dissolution | |
| Tang et al. | Chitosan-Based Microneedle Patch with Multi-Anchoring and Integrated Hemostatic Mechanisms for Highly Efficient Bleeding Control in Dynamic, Wet Intestinal Conditions | |
| Jeong et al. | Injectable Thermosensitive Chitosan Solution with p-Glycerophosphate as an Optimal Submucosal Fluid Cushion for Endoscopic Submucosal Dissection. Polymers 2021, 13, 1696 | |
| HK1135609A1 (en) | Formation of medically useful gels comprising microporous particles and methods of use |